Alert

Clinical Trial Details Page

PENELOPE B54-i

Objective

Phase III Study Evaluating Palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in Patients With Hormone-receptor-positive, HER2-normal Primary Breast Cancer With High Relapse Risk After Neoadjuvant Chemotherapy "PENELOPEB"

IRB Protocol Number
NCT01864746

Clinical Trial Categories

  • Breast Cancer
Contact
Nancy Burns at 919-784-7209
or Nancy.Burns2@unchealth.unc.edu
How to Participate

View eligibility criteria and additional study information.

Related Locations

Top